Blaze Bioscience snags $9M Series B for tumor illumination tech; Venture firm splits in two;

@FierceMedDev: Volcano green-lights a $200M share buyback under M&A pressure. News | Follow @FierceMedDev

@MarkHFierce: Inogen joins a select group of med device companies that have filed IPO plans this year. Article | Follow @MarkHFierce

@MichaelGFierce: Check out FierceBiotech's Top Women in Biotech 2013. More | Follow @MichaelGFierce

@GalenMoore: Xlumena brings in hedge fund Third Point for a $25M Series C aimed at FDA approval. Story | Follow @GalenMoore

> Blaze Bioscience snagged $9 million in Series B financing for its Tumor Paint technology, a combination optide and fluorescent dye that helps illuminate cancer cells during surgery. Item

> AcelRx is aiming for a Sept. 2014 approval date for its handheld, automated, pre-programmed pain drug delivery system. Story

> A group with Burrill & Company, a San Francisco VC, has split off into a new venture firm called Biomark Capital. Story

> Medgenics' board chairman has purchased more than 20,000 shares of the company's common stock. Item

> German researchers took a step toward developing better hearing aids by building a computer model of acoustic coding in the inner ear and the neuronal information processing by the brain stem. Item

Biotech News

@FierceBiotech: Xencor Prices Initial Public Offering. Release | Follow @FierceBiotech

@JohnCFierce: Sanofi is touting U300 PhIII diabetes data. Important program for the co. Release (PDF) | Follow @JohnCFierce

@DamianFierce: Kinda disappointed Celgene couldn't get more arcane clauses into this OncoMed deal. Story | Follow @DamianFierce

@EmilyMFierce: Male contraceptive breakthrough: Australian, UK researchers collaborate on protein discovery. More | Follow @EmilyMFierce

> Sanofi touts promising PhIII data on next-gen diabetes therapy as rivals circle. Story

> Angel investors ante up $9M to fuel Blaze's early-stage program for 'tumor paint'. Report

> Novo CEO claims 'strong' pipeline effort will boost sales. Item

Pharma News

@FiercePharma: FDA Grants Astellas Qualified Infectious Disease Product Designation for Isavuconazole. Release | Follow @FiercePharma

@EricPFierce: Takeda tries on outsider for CEO. Forest tees up cuts. GSK's Witty heads to China. Read it in FiercePharma. More | Follow @EricPFierce

@CarlyHFierce: ICYMI in FierceBiomarkers: Protein C4d linked to higher mortality rates in lung cancer patients. Story | Follow @CarlyHFierce

> Pfizer keeps piling onto consumer health business. Story

> Sources: Bayer, others kicking tires on Novartis animal health business. Article

> Novo expects to keep pumping out growth in insulin market. More

Pharma Manufacturing News

> Irish plant shutdown move puts another Merck site on the block. More

> Wockhardt braces for lost sales after FDA bans its main plant. Story

> Gland Pharma targets U.S. injectables sector after securing $200M. Article

> India drops plans to limit foreign ownership of production capacity. News

> FDA outlines plans for new compounding pharmacy powers. Report

> Hedge fund ups the ante in game of chicken with McKesson. Item

Biotech Research News

> NIH announces $100M for new HIV research initiative. Story

> Key hep C protein revealed, paving the way for new vaccines. News

> Novartis team IDs new malaria target. Article

> NIH publishes first Alzheimer's genomics data for researchers. Report

> Male contraceptive breakthrough: Australian, UK researchers collaborate on protein discovery. More

> Study: Standardization needed for drug screening studies. Item

Suggested Articles

Johnson & Johnson Vision announced that the worldwide president of its surgical business, Tom Frinzi, plans to retire at the end of this year.

Philips looked back on 15 years of data from one of its telehealth-equipped intensive care units, where centralizing operations reduced mortality.

Sanofi will look to pull back from its three-year-old relationship with Verily and their virtual diabetes clinic, Onduo.